QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04)

被引：0
|
作者：
Kosmala, R. [1 ]
Fokas, E. [2 ,3 ]
Flentje, M. [1 ]
Sauer, R. [4 ]
Liersch, T. [5 ]
Graeven, U. [6 ]
Fietkau, R. [4 ]
Hohenberger, W. [7 ]
Arnold, D. [8 ]
Hofheinz, R. [9 ]
Ghadimi, M. [5 ]
Raab, H. [10 ]
Stroebel, P. [11 ]
Staib, L. [12 ]
Grabenbauer, G. G. [13 ]
Folprecht, G. [14 ]
Uter, W. [15 ]
Gall, C. [15 ]
Roedel, C. [2 ,3 ]
Polat, B. [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Radiat Oncol, Wurzburg, Germany
[2] Goethe Univ Frankfurt, Frankfurt, Germany
[3] German Canc Consortium DKTK Partner Site, Dept Radiotherapy & Oncol, Frankfurt, Germany
[4] Univ Hosp Erlangen, Dept Radiat Oncol, Erlangen, Germany
[5] Univ Med Ctr Gottingen, Dept Gen Visceral & Paediat Surg, Gottingen, Germany
[6] Kliniken Maria Hilf GmbH Monchengladbach, Dept Haematol Oncol & Gastroenterol, Monchengladbach, Germany
[7] Univ Hosp Erlangen, Dept Surg, Erlangen, Germany
[8] Tumour Biol Ctr Freiburg, Freiburg, Germany
[9] Heidelberg Univ, Univ Hosp Mannheim, Interdisciplinary Tumour Ctr, Heidelberg, Germany
[10] Carl von Ossietzky Univ Oldenburg, Dept Gen & Visceral Surg, Oldenburg, Germany
[11] Univ Med Ctr Gottingen, Inst Pathol, Gottingen, Germany
[12] Klinikum Esslingen, Dept Surg, Esslingen, Germany
[13] DiaCura & Klinikum Coburg, Dept Radiat Oncol & Radiotherapy, Coburg, Germany
[14] Univ Hosp Carl Gustav Carus, Univ Canc Ctr, Med Dept 1, Dresden, Germany
[15] Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Erlangen, Germany
来源：
RADIOTHERAPY AND ONCOLOGY | 2019年 / 133卷
关键词：
D O I：
10.1016/S0167-8140(19)30804-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OC-0384
引用
收藏
页码：S191 / S192
页数：2
相关论文
共 50 条
  • [21] Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial
    Diefenhardt, Markus
    Ludmir, Ethan B.
    Hofheinz, Ralf-Dieter
    Ghadimi, Michael
    Minsky, Bruce D.
    Fleischmann, Max
    Fokas, Emmanouil
    Rodel, Claus
    RADIOTHERAPY AND ONCOLOGY, 2021, 164 : 223 - 231
  • [22] Importance of the Body Mass Index on the Therapy cycle, the operative Result and the long-term clinical Outcome in the multimodal Treatment of Patients with Rectal Cancer. A secondary Analysis of the randomized-Phase III CAO/ARO/AIO-04 Rectal Cancer Study
    Diefenhardt, M.
    Ludmir, E.
    Hofheinz, R-D
    Ghadimi, M.
    Minsky, B.
    Fleischmann, M.
    Fokas, E.
    Roedel, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S35 - S36
  • [23] Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
    Roedel, Claus
    Graeven, Ullrich
    Fietkau, Rainer
    Hohenberger, Werner
    Hothorn, Torsten
    Arnold, Dirk
    Hofheinz, Ralf-Dieter
    Ghadimi, Michael
    Wolff, Hendrik A.
    Lang-Welzenbach, Marga
    Raab, Hans-Rudolf
    Wittekind, Christian
    Stroebel, Philipp
    Staib, Ludger
    Wilhelm, Martin
    Grabenbauer, Gerhard G.
    Manns, Hans Hoff
    Lindemann, Fritz
    Schlenska-Lange, Anke
    Folprecht, Gunnar
    Sauer, Rolf
    Liersch, Torsten
    Sauer, R.
    Hohenberger, W.
    Fietkau, R.
    Lahmer, G.
    Golcher, H.
    Klautke, G.
    Hartmann, A.
    Rau, T.
    Keilholz, L.
    Henneking, K.
    Muehldorfer, S.
    Klein, S.
    Stolte, M.
    Staar, S.
    Lehnert, T.
    Hertenstein, B.
    Freys, S. M.
    Pflueger, K.-H.
    Sendt, W.
    Teyssen, S.
    Latz, D.
    Leibl, B. J.
    Matek, W.
    Grabenbauer, G. G.
    Alfrink, M.
    Kreczy, A.
    Strobel, G. F.
    Düwel, H.-J.
    LANCET ONCOLOGY, 2015, 16 (08): : 979 - 989
  • [24] Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial
    Roedel, C.
    Liersch, T.
    Becker, H.
    Fietkau, R.
    Hohenberger, W.
    Hothorn, T.
    Graeven, U.
    Arnold, D.
    Raab, H. -R
    Wittekind, C.
    Staib, L.
    Hess, C.
    Grabenbauer, G.
    Sauer, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 5 - 5
  • [25] Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial
    Roedel, C.
    Becker, H.
    Fietkau, R.
    Graeven, U.
    Hohenberger, W.
    Hothorn, T.
    Lang-Welzenbach, M.
    Liersch, T.
    Staib, L.
    Christiansen, H.
    Wittekind, C.
    Sauer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [26] Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial
    Roedel, C.
    Becker, H.
    Fietkau, R.
    Graeven, U.
    Hohenberger, W.
    Hothorn, T.
    Lang-Welzenbach, M.
    Liersch, T.
    Staib, L.
    Christiansen, H.
    Wittekind, C.
    Sauer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial.
    Rodel, Claus
    Liersch, Torsten
    Fietkau, Rainer
    Hohenberger, Werner
    Graeven, Ullrich
    Hothorn, Torsten
    Arnold, Dirk
    Raab, Hans-Rudolf
    Wittekind, Christian
    Hess, Clemens F.
    Staib, Ludger
    Becker, Heinz
    Sauer, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin vs. 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial
    Roedel, C.
    Larsch, T.
    Becker, H.
    Fietkau, R.
    Hohenberger, W.
    Hothorn, T.
    Graeven, U.
    Arnold, D.
    Lang-Welzenbach, M.
    Raab, H. -R
    Suelberg, H.
    Wittekind, C.
    Potapov, S.
    Staib, L.
    Hess, C. F.
    Weigang-Koehler, K.
    Grabenbauer, G. G.
    Hoffmans, H.
    Lindemann, F.
    Schlenska-Lange, A.
    Folprecht, G.
    Sauer, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 38 - 38
  • [29] Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO 04) a comparison between two multicenter randomized phase II/III trials
    Diefenhardt, Markus
    Fleischmann, Maximillian
    Martin, Daniel
    Hofheinz, Ralf-Dieter
    Piso, Pompiliu
    Germer, Christoph-Thomas
    Hambsch, Peter
    Gruetzmann, Robert
    Kirste, Simon
    Schlenska-Lange, Anke
    Ghadimi, Michael
    Roedel, Claus
    Fokas, Emmanouil
    RADIOTHERAPY AND ONCOLOGY, 2023, 179
  • [30] Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer: Results of the CAO/ARO/AIO-04 multicentre, open-label, randomised, phase 3 trial
    Fokas, E.
    Stroebel, P.
    Fietkau, R.
    Ghadimi, M.
    Liersch, T.
    Grabenbauer, G.
    Hartmann, A.
    Kaufmann, M.
    Sauer, R.
    Graeven, U.
    Hoffmanns, H.
    Raab, H-R
    Hothorn, T.
    Wittekind, C.
    Roedel, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S31 - S31
12345